Wang Z, et al. - Researchers assessed the potential predictive value of serum galectin 3 (Gal-3) for severe abdominal aortic calcification (AAC) as well as AAC progression in maintenance hemodialysis (MHD) patients by analyzing a prospective cohort. Participants (n = 152) had received hemodialysis at the Blood Purification Center of Ruijin Hospital and were observed for 3 years. The study sample included about 59.9% male, and the median age was 60 (50–67) years. Two AAC evaluations were done: one at baseline and one following the 3-year follow-up period. Serum Gal-3 was identified as an independent risk factor for both follow-up severe AAC and AAC progression, in logistic regression analysis. Findings revealed a correlation of serum Gal-3 with vascular calcification in end-stage renal disease patients. The possible use of Gal-3 as a potential biomarker of vascular calcification for MHD patients was also suggested.